FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360999727> ?p ?o ?g. }

• W4360999727 endingPage "e070240" @default.
• W4360999727 startingPage "e070240" @default.
• W4360999727 abstract "Previous studies demonstrated that the implementation of the Kidney Disease Improving Global Outcomes (KDIGO) guideline-based bundle, consisting of different supportive measures in patients at high risk for acute kidney injury (AKI), might reduce rate and severity of AKI after surgery. However, the effects of the care bundle in broader population of patients undergoing surgery require confirmation.The BigpAK-2 trial is an international, randomised, controlled, multicentre trial. The trial aims to enrol 1302 patients undergoing major surgery who are subsequently admitted to the intensive care or high dependency unit and are at high-risk for postoperative AKI as identified by urinary biomarkers (tissue inhibitor of metalloproteinases 2*insulin like growth factor binding protein 7 (TIMP-2)*IGFBP7)). Eligible patients will be randomised to receive either standard of care (control) or a KDIGO-based AKI care bundle (intervention). The primary endpoint is the incidence of moderate or severe AKI (stage 2 or 3) within 72 hours after surgery, according to the KDIGO 2012 criteria. Secondary endpoints include adherence to the KDIGO care bundle, occurrence and severity of any stage of AKI, change in biomarker values during 12 hours after initial measurement of (TIMP-2)*(IGFBP7), number of free days of mechanical ventilation and vasopressors, need for renal replacement therapy (RRT), duration of RRT, renal recovery, 30-day and 60-day mortality, intensive care unit length-of-stay and hospital length-of-stay and major adverse kidney events. An add-on study will investigate blood and urine samples from recruited patients for immunological functions and kidney damage.The BigpAK-2 trial was approved by the Ethics Committee of the Medical Faculty of the University of Münster and subsequently by the corresponding Ethics Committee of the participating sites. A study amendment was approved subsequently. In the UK, the trial was adopted as an NIHR portfolio study. Results will be disseminated widely and published in peer-reviewed journals, presented at conferences and will guide patient care and further research.NCT04647396." @default.
• W4360999727 created "2023-03-30" @default.
• W4360999727 creator A5000766210 @default.
• W4360999727 creator A5002056568 @default.
• W4360999727 creator A5002144514 @default.
• W4360999727 creator A5004350578 @default.
• W4360999727 creator A5008629517 @default.
• W4360999727 creator A5009667317 @default.
• W4360999727 creator A5012239760 @default.
• W4360999727 creator A5019726220 @default.
• W4360999727 creator A5020171810 @default.
• W4360999727 creator A5021022035 @default.
• W4360999727 creator A5021025682 @default.
• W4360999727 creator A5021889777 @default.
• W4360999727 creator A5023483618 @default.
• W4360999727 creator A5025235476 @default.
• W4360999727 creator A5025581494 @default.
• W4360999727 creator A5027079998 @default.
• W4360999727 creator A5027215688 @default.
• W4360999727 creator A5029554897 @default.
• W4360999727 creator A5031471398 @default.
• W4360999727 creator A5031945158 @default.
• W4360999727 creator A5039944374 @default.
• W4360999727 creator A5040663446 @default.
• W4360999727 creator A5040689704 @default.
• W4360999727 creator A5054301578 @default.
• W4360999727 creator A5055659856 @default.
• W4360999727 creator A5060341016 @default.
• W4360999727 creator A5061657411 @default.
• W4360999727 creator A5061798549 @default.
• W4360999727 creator A5068174451 @default.
• W4360999727 creator A5072101286 @default.
• W4360999727 creator A5074127761 @default.
• W4360999727 creator A5079379783 @default.
• W4360999727 creator A5081402185 @default.
• W4360999727 creator A5084110893 @default.
• W4360999727 creator A5084499631 @default.
• W4360999727 creator A5086607946 @default.
• W4360999727 creator A5086916502 @default.
• W4360999727 creator A5087520906 @default.
• W4360999727 creator A5091473620 @default.
• W4360999727 date "2023-03-01" @default.
• W4360999727 modified "2023-10-17" @default.
• W4360999727 title "Biomarker-guided intervention to prevent acute kidney injury after major surgery (BigpAK-2 trial): study protocol for an international, prospective, randomised controlled multicentre trial" @default.
• W4360999727 cites W2003034890 @default.
• W4360999727 cites W2077967941 @default.
• W4360999727 cites W2108696783 @default.
• W4360999727 cites W2262478348 @default.
• W4360999727 cites W2400168554 @default.
• W4360999727 cites W2582602949 @default.
• W4360999727 cites W2750703770 @default.
• W4360999727 cites W2810817334 @default.
• W4360999727 cites W2980801506 @default.
• W4360999727 cites W2999166570 @default.
• W4360999727 cites W3133528108 @default.
• W4360999727 cites W3133933796 @default.
• W4360999727 cites W4205225401 @default.
• W4360999727 cites W4236805817 @default.
• W4360999727 cites W4292528167 @default.
• W4360999727 doi "https://doi.org/10.1136/bmjopen-2022-070240" @default.
• W4360999727 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36972972" @default.
• W4360999727 hasPublicationYear "2023" @default.
• W4360999727 type Work @default.
• W4360999727 citedByCount "0" @default.
• W4360999727 crossrefType "journal-article" @default.
• W4360999727 hasAuthorship W4360999727A5000766210 @default.
• W4360999727 hasAuthorship W4360999727A5002056568 @default.
• W4360999727 hasAuthorship W4360999727A5002144514 @default.
• W4360999727 hasAuthorship W4360999727A5004350578 @default.
• W4360999727 hasAuthorship W4360999727A5008629517 @default.
• W4360999727 hasAuthorship W4360999727A5009667317 @default.
• W4360999727 hasAuthorship W4360999727A5012239760 @default.
• W4360999727 hasAuthorship W4360999727A5019726220 @default.
• W4360999727 hasAuthorship W4360999727A5020171810 @default.
• W4360999727 hasAuthorship W4360999727A5021022035 @default.
• W4360999727 hasAuthorship W4360999727A5021025682 @default.
• W4360999727 hasAuthorship W4360999727A5021889777 @default.
• W4360999727 hasAuthorship W4360999727A5023483618 @default.
• W4360999727 hasAuthorship W4360999727A5025235476 @default.
• W4360999727 hasAuthorship W4360999727A5025581494 @default.
• W4360999727 hasAuthorship W4360999727A5027079998 @default.
• W4360999727 hasAuthorship W4360999727A5027215688 @default.
• W4360999727 hasAuthorship W4360999727A5029554897 @default.
• W4360999727 hasAuthorship W4360999727A5031471398 @default.
• W4360999727 hasAuthorship W4360999727A5031945158 @default.
• W4360999727 hasAuthorship W4360999727A5039944374 @default.
• W4360999727 hasAuthorship W4360999727A5040663446 @default.
• W4360999727 hasAuthorship W4360999727A5040689704 @default.
• W4360999727 hasAuthorship W4360999727A5054301578 @default.
• W4360999727 hasAuthorship W4360999727A5055659856 @default.
• W4360999727 hasAuthorship W4360999727A5060341016 @default.
• W4360999727 hasAuthorship W4360999727A5061657411 @default.
• W4360999727 hasAuthorship W4360999727A5061798549 @default.
• W4360999727 hasAuthorship W4360999727A5068174451 @default.
• W4360999727 hasAuthorship W4360999727A5072101286 @default.
• W4360999727 hasAuthorship W4360999727A5074127761 @default.
• W4360999727 hasAuthorship W4360999727A5079379783 @default.
• W4360999727 hasAuthorship W4360999727A5081402185 @default.

• next